

GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion.
You can purchase shares of GH Research (NASDAQ:GHRS) through any online brokerage.
Other companies in GH Research’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
GH Research has a consensus price target of $40.50.
The stock price for GH Research (NASDAQ: GHRS) is $18.61 last updated November 6, 2026 at 4:00 PM EST.
There are no upcoming dividends for GH Research.
GH Research does not have any upcoming earnings scheduled.
There is no upcoming split for GH Research.
GH Research is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies...